Relationship of uric acid, C-reactive protein, and N-terminal pro-B-type natriuretic peptide with acute cerebral infarction

Li, Gang; Han, Chong; Xia, Xiangping; Yao, Shengtao

doi:10.1590/1806-9282.20210693

Cited by 3 publications

(2 citation statements)

References 17 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sometimes, ischemic stroke appeared without obvious causes, then NT-proBNP may indicate that a paroxysmal atrial brillation might lead to the incident [24][25][26][27] . There are also some studies on the relationship between BNP and the prognosis of stroke patients 28 , with follow-up time of months to years 7,[29][30][31] , however, there is currently no research on the short-term prognosis of BNP in critically ill patients.…”

Section: Discussionmentioning

confidence: 99%

Association of NT-proBNP and 7-day mortality of patients with acute ischemic stroke in intensive care unit: a retrospective cohort study

zhang,

Liu,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Acute ischemic stroke (AIS) results in high mortality, especially among patients admitted to the intensive care unit. Previous research has shown the relationship of N-terminal pro-B-type natriuretic peptide (NT-proBNP) with stroke. However, unlike in heart disease, few research has related NT-proBNP with severity and prognosis of patients with AIS in the intensive care unit. This study aimed to investigate the relation between NT-proBNP, which is widely used in heart disease, and the short-term mortality of patients with AIS in critical care unit. This retrospective study was based on Medical Information Mart for Intensive Care (MIMIC)-IV. The main outcome was defined as mortality in seven days and the secondary outcomes were defined as ventricular tachycardia and performance of endotracheal tube. Patients diagnosed with acute ischemic stroke and acute cerebral infarction were extracted based on the 9th and 10th versions of ICD codes. If the patient was treated multiple times in the ICU, only the data of the first admission to the ICU will be taken for research and analysis. The level of NT-proBNP was significantly associated with 7-day all-cause mortality in patients with AIS, the HR was 1.84 ([95% CI, 1.11–3.07], P = 0.019). After excluding patients with heart failure, NT-proBNP showed significant association with 7-day all-cause mortality, the HR was 2.71 ([95% CI, 1.15–6.37], P = 0.022). There was no significant association between NT-proBNP and secondary outcomes. In patients with AIS in intensive care unit, higher levels of NT-proBNP related with a higher mortality. NT-proBNP might serve as a biomarker that help to predict the short-term mortality among the patients with AIS in intensive care unit.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of NT-proBNP and 7-day mortality of patients with acute ischemic stroke in intensive care unit: a retrospective cohort study

zhang,

Liu,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…It is suggested that D-dimer and CRP levels may be associated with the severity of AIS in patients with COVID-19 [61,62] . Hence, for patients with hypercoagulable states, proper use of antithrombotic agents or antithrombotic therapy could be effective [63,64] .…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics and outcomes of acute ischemic stroke in patients with COVID-19: A systematic review and meta-analysis of global data

Yao¹,

Huang²,

Chen³

et al. 2022

Adv Neuro

View full text Add to dashboard Cite

Objective. There is increased concern regarding acute ischemic stroke (AIS) in patients with coronavirus disease 2019 (COVID-19). The aim of this study was to depict the manifestations and outcomes of COVID-19-associated AIS. Methods. We systematically searched for eligible studies describing AIS in patients with COVID-19 using PubMed, Embase, and Web of Science up to November 29, 2021. We complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and used the Newcastle–Ottawa Scale to assess data quality. The data were pooled using fixed- and random-effects models. Results. Thirty-eight eligible studies involving 76,894 participants were included in this meta-analysis. Compared with AIS patients who did not have COVID-19, patients with COVID-19 were more likely to have anterior circulation stroke (odds ratio [OR]: 2.29, 95% confidence interval [CI]: 1.03 – 5.10; I2: 37%), particularly involving the internal carotid artery (OR: 1.85, 95% CI: 1.19 – 2.88; I2: 0); more severe neurological deficit (National Institutes of Health Stroke Scale [NIHSS]) (weighted mean difference [WMD]: 3.21, 95% CI: 2.13 – 4.29; I2: 64%); higher proportion of cryptogenic stroke (OR: 1.83, 95% CI: 1.24 – 2.70; I2: 62%), large vessel occlusion (OR: 1.68, 95% CI: 1.10 – 2.57; I2: 75%), and multi-territory involvement (OR: 2.64, 95% CI: 1.62 – 4.29; I2: 0%); higher C-reactive protein levels (WMD: 55.90, 95% CI: 33.32 – 78.49; I2: 67%), and D-dimer levels (standardized mean difference: 0.81, 95% CI: 0.52 – 1.10; I2: 59%). The proportion of poor outcomes were higher among patients with COVID-19, including increased risk of in-hospital death (OR: 3.70, 95% CI: 2.73 – 5.02; I2: 64%) and lower possibility of favorable discharge (OR: 0.49, 95% CI: 0.39 – 0.61; I2: 0). However, COVID-19 did not increase the risk of hemorrhagic transformation (OR: 1.34, 95% CI: 0.91 – 1.98; I2: 39%) and symptomatic intracerebral hemorrhage (OR: 1.46, 95% CI: 0.81 – 2.62; I2: 0). Conclusion. AIS patients with COVID-19 seem to display a pattern of large vessel occlusion and multi-territory infarcts. These patients have high inflammatory marker levels and increased D-dimer levels, which implies that thrombosis and/or thromboembolism might be the underlying mechanism. These patients tend to have worse prognosis regardless of whether they receive reperfusion treatment.

show abstract

Clinical Effect of Butylphthalide Combined with Rt-PA Intravenous Thrombolysis in the Treatment of Acute Cerebral Infarction

Zhou¹,

Yang²,

Liu³

et al. 2022

Applied Bionics and Biomechanics

View full text Add to dashboard Cite

Objective. To assess the clinical effect of butylphthalide combined with rt-PA intravenous thrombolysis in the treatment of acute cerebral infarction (ACI). Methods. Totally, 312 acute cerebral infarction patients were included in this research. Those in the group for experiment received butylphthalide (25 mg QD) combined with rt-PA intravenous thrombolysis (0.9 mg/kg QD), while the control group received rt-PA intravenous ( P < 0.05 ). Moreover, NIHSS (NIH Stroke Scale/Score) and Barthel index scores in the two groups improved, NIHSS score had ameliorated, and Barthel index score was higher than that in the reference group ( P < 0.05 ). Conclusion. The combination of butylphthalide and recombination plasminogen activator alteplase (rt-PA) intravenous thrombolysis has a significant clinical effect in the treatment of acute cerebral infarction. It can alleviate the inflammatory symptoms, accelerate the recovery of neurological function, and improve the ability of daily living.

show abstract

Relationship of uric acid, C-reactive protein, and N-terminal pro-B-type natriuretic peptide with acute cerebral infarction

Cited by 3 publications

References 17 publications

Association of NT-proBNP and 7-day mortality of patients with acute ischemic stroke in intensive care unit: a retrospective cohort study

Association of NT-proBNP and 7-day mortality of patients with acute ischemic stroke in intensive care unit: a retrospective cohort study

Clinical characteristics and outcomes of acute ischemic stroke in patients with COVID-19: A systematic review and meta-analysis of global data

Clinical Effect of Butylphthalide Combined with Rt-PA Intravenous Thrombolysis in the Treatment of Acute Cerebral Infarction

Contact Info

Product

Resources

About